Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis
Abstract Aims Although tafamidis is used in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), its specific effect on cardiac function is unclear. Thus, this study aimed to investigate the effect of tafamidis on left atrial (LA) and left ventricular function using speckle-trackin...
Gespeichert in:
| Veröffentlicht in: | European heart journal cardiovascular imaging 2024-04, Vol.25 (5), p.678-686 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 686 |
|---|---|
| container_issue | 5 |
| container_start_page | 678 |
| container_title | European heart journal cardiovascular imaging |
| container_volume | 25 |
| creator | Nishizawa, Rosy Haruna Kawano, Hiroaki Yoshimuta, Tsuyoshi Eguchi, Chisa Kojima, Sanae Minami, Takako Sato, Daisuke Eguchi, Masamichi Okano, Shinji Ikeda, Satoshi Ueda, Mitsuharu Maemura, Koji |
| description | Abstract
Aims
Although tafamidis is used in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), its specific effect on cardiac function is unclear. Thus, this study aimed to investigate the effect of tafamidis on left atrial (LA) and left ventricular function using speckle-tracking echocardiography for 1 year of treatment in patients with ATTRwt-CA.
Methods and results
We included 23 patients (mean age, 76 years) with ATTRwt-CA confirmed via biopsy. We analysed the left ventricular and LA strain using 2D speckle-tracking echocardiography and compared these parameters before and 1 year after starting treatment with tafamidis between 16 patients with sinus rhythm (SR) and 7 patients with atrial fibrillation (AF). In ATTRwt-CA patients with SR, LA reservoir strain significantly improved by 1-year tafamidis treatment (10.5 ± 5.0% to 11.9 ± 5.3%, P = 0.0307) although global longitudinal strain (GLS) did not (−10.6 ± 3.1% to −11.3 ± 3.0%, P = 0.0608). In contrast, LA reservoir strain was not significantly changed (5.4 ± 2.9% to 4.9 ± 1.7%, P = 0.4571), and GLS deteriorated (−8.4 ± 2.3% to −6.8 ± 1.4%, P = 0.0267) in ATTRwt-CA patients with AF.
Conclusion
LA function improved with tafamidis treatment in ATTRwt-CA patients with SR but not left ventricular function. However, these cardiac functions did not improve with tafamidis treatment in ATTRwt-CA patients with AF.
Graphical Abstract
Graphical Abstract |
| doi_str_mv | 10.1093/ehjci/jead344 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2903859413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ehjci/jead344</oup_id><sourcerecordid>2903859413</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-85b15bf9854abc9fd4d28979dbeac5ae10c29f08808298c3e1d0247745d464113</originalsourceid><addsrcrecordid>eNqFkD1PBCEQhonRqFFLW0Npsx6wrAulMX4lJjZab2ZhyHHZL4HVXOdPF71TSydkBibPvBNeQk45u-BMlwtcroxfrBBsKeUOORRM1oWQXOz-3pk8ICcxrliOSl5KwffJQanyuNT1Ifm4cQ5NinR0NIGD3lufHwNNS6QdukTfcEjBm7mDQGGwmybkFnQ0pgB-oPlMkHwGI333aZlTZ4u0npBmYIhpuQ6YMmUgWA-GQr_uRm_H6OMx2XPQRTzZ1iPycnvzfH1fPD7dPVxfPRZGKJEKVbW8ap1WlYTWaGelFUrX2rYIpgLkzAjtmFJMCa1MidwyIetaVjZ_mvPyiJxvdKcwvs4YU9P7aLDrYMBxjo3QrFSVlrzMaLFBTRhjDOiaKfgewrrhrPnyvfn2vdn6nvmzrfTc9mh_6R-X_3aP8_SP1idodY_n</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2903859413</pqid></control><display><type>article</type><title>Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Nishizawa, Rosy Haruna ; Kawano, Hiroaki ; Yoshimuta, Tsuyoshi ; Eguchi, Chisa ; Kojima, Sanae ; Minami, Takako ; Sato, Daisuke ; Eguchi, Masamichi ; Okano, Shinji ; Ikeda, Satoshi ; Ueda, Mitsuharu ; Maemura, Koji</creator><creatorcontrib>Nishizawa, Rosy Haruna ; Kawano, Hiroaki ; Yoshimuta, Tsuyoshi ; Eguchi, Chisa ; Kojima, Sanae ; Minami, Takako ; Sato, Daisuke ; Eguchi, Masamichi ; Okano, Shinji ; Ikeda, Satoshi ; Ueda, Mitsuharu ; Maemura, Koji</creatorcontrib><description>Abstract
Aims
Although tafamidis is used in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), its specific effect on cardiac function is unclear. Thus, this study aimed to investigate the effect of tafamidis on left atrial (LA) and left ventricular function using speckle-tracking echocardiography for 1 year of treatment in patients with ATTRwt-CA.
Methods and results
We included 23 patients (mean age, 76 years) with ATTRwt-CA confirmed via biopsy. We analysed the left ventricular and LA strain using 2D speckle-tracking echocardiography and compared these parameters before and 1 year after starting treatment with tafamidis between 16 patients with sinus rhythm (SR) and 7 patients with atrial fibrillation (AF). In ATTRwt-CA patients with SR, LA reservoir strain significantly improved by 1-year tafamidis treatment (10.5 ± 5.0% to 11.9 ± 5.3%, P = 0.0307) although global longitudinal strain (GLS) did not (−10.6 ± 3.1% to −11.3 ± 3.0%, P = 0.0608). In contrast, LA reservoir strain was not significantly changed (5.4 ± 2.9% to 4.9 ± 1.7%, P = 0.4571), and GLS deteriorated (−8.4 ± 2.3% to −6.8 ± 1.4%, P = 0.0267) in ATTRwt-CA patients with AF.
Conclusion
LA function improved with tafamidis treatment in ATTRwt-CA patients with SR but not left ventricular function. However, these cardiac functions did not improve with tafamidis treatment in ATTRwt-CA patients with AF.
Graphical Abstract
Graphical Abstract</description><identifier>ISSN: 2047-2404</identifier><identifier>EISSN: 2047-2412</identifier><identifier>DOI: 10.1093/ehjci/jead344</identifier><identifier>PMID: 38109497</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><subject>Aged ; Aged, 80 and over ; Amyloid Neuropathies, Familial - complications ; Amyloid Neuropathies, Familial - diagnostic imaging ; Amyloid Neuropathies, Familial - drug therapy ; Atrial Fibrillation - diagnostic imaging ; Atrial Fibrillation - drug therapy ; Benzoxazoles - therapeutic use ; Cardiomyopathies - diagnostic imaging ; Cardiomyopathies - drug therapy ; Cohort Studies ; Echocardiography ; Female ; Humans ; Male ; Treatment Outcome ; Ventricular Dysfunction, Left - diagnostic imaging ; Ventricular Dysfunction, Left - drug therapy ; Ventricular Dysfunction, Left - physiopathology</subject><ispartof>European heart journal cardiovascular imaging, 2024-04, Vol.25 (5), p.678-686</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c282t-85b15bf9854abc9fd4d28979dbeac5ae10c29f08808298c3e1d0247745d464113</cites><orcidid>0000-0002-4945-675X ; 0000-0002-0452-4384 ; 0000-0001-8163-8038</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38109497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishizawa, Rosy Haruna</creatorcontrib><creatorcontrib>Kawano, Hiroaki</creatorcontrib><creatorcontrib>Yoshimuta, Tsuyoshi</creatorcontrib><creatorcontrib>Eguchi, Chisa</creatorcontrib><creatorcontrib>Kojima, Sanae</creatorcontrib><creatorcontrib>Minami, Takako</creatorcontrib><creatorcontrib>Sato, Daisuke</creatorcontrib><creatorcontrib>Eguchi, Masamichi</creatorcontrib><creatorcontrib>Okano, Shinji</creatorcontrib><creatorcontrib>Ikeda, Satoshi</creatorcontrib><creatorcontrib>Ueda, Mitsuharu</creatorcontrib><creatorcontrib>Maemura, Koji</creatorcontrib><title>Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis</title><title>European heart journal cardiovascular imaging</title><addtitle>Eur Heart J Cardiovasc Imaging</addtitle><description>Abstract
Aims
Although tafamidis is used in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), its specific effect on cardiac function is unclear. Thus, this study aimed to investigate the effect of tafamidis on left atrial (LA) and left ventricular function using speckle-tracking echocardiography for 1 year of treatment in patients with ATTRwt-CA.
Methods and results
We included 23 patients (mean age, 76 years) with ATTRwt-CA confirmed via biopsy. We analysed the left ventricular and LA strain using 2D speckle-tracking echocardiography and compared these parameters before and 1 year after starting treatment with tafamidis between 16 patients with sinus rhythm (SR) and 7 patients with atrial fibrillation (AF). In ATTRwt-CA patients with SR, LA reservoir strain significantly improved by 1-year tafamidis treatment (10.5 ± 5.0% to 11.9 ± 5.3%, P = 0.0307) although global longitudinal strain (GLS) did not (−10.6 ± 3.1% to −11.3 ± 3.0%, P = 0.0608). In contrast, LA reservoir strain was not significantly changed (5.4 ± 2.9% to 4.9 ± 1.7%, P = 0.4571), and GLS deteriorated (−8.4 ± 2.3% to −6.8 ± 1.4%, P = 0.0267) in ATTRwt-CA patients with AF.
Conclusion
LA function improved with tafamidis treatment in ATTRwt-CA patients with SR but not left ventricular function. However, these cardiac functions did not improve with tafamidis treatment in ATTRwt-CA patients with AF.
Graphical Abstract
Graphical Abstract</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amyloid Neuropathies, Familial - complications</subject><subject>Amyloid Neuropathies, Familial - diagnostic imaging</subject><subject>Amyloid Neuropathies, Familial - drug therapy</subject><subject>Atrial Fibrillation - diagnostic imaging</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Benzoxazoles - therapeutic use</subject><subject>Cardiomyopathies - diagnostic imaging</subject><subject>Cardiomyopathies - drug therapy</subject><subject>Cohort Studies</subject><subject>Echocardiography</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Treatment Outcome</subject><subject>Ventricular Dysfunction, Left - diagnostic imaging</subject><subject>Ventricular Dysfunction, Left - drug therapy</subject><subject>Ventricular Dysfunction, Left - physiopathology</subject><issn>2047-2404</issn><issn>2047-2412</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkD1PBCEQhonRqFFLW0Npsx6wrAulMX4lJjZab2ZhyHHZL4HVXOdPF71TSydkBibPvBNeQk45u-BMlwtcroxfrBBsKeUOORRM1oWQXOz-3pk8ICcxrliOSl5KwffJQanyuNT1Ifm4cQ5NinR0NIGD3lufHwNNS6QdukTfcEjBm7mDQGGwmybkFnQ0pgB-oPlMkHwGI333aZlTZ4u0npBmYIhpuQ6YMmUgWA-GQr_uRm_H6OMx2XPQRTzZ1iPycnvzfH1fPD7dPVxfPRZGKJEKVbW8ap1WlYTWaGelFUrX2rYIpgLkzAjtmFJMCa1MidwyIetaVjZ_mvPyiJxvdKcwvs4YU9P7aLDrYMBxjo3QrFSVlrzMaLFBTRhjDOiaKfgewrrhrPnyvfn2vdn6nvmzrfTc9mh_6R-X_3aP8_SP1idodY_n</recordid><startdate>20240430</startdate><enddate>20240430</enddate><creator>Nishizawa, Rosy Haruna</creator><creator>Kawano, Hiroaki</creator><creator>Yoshimuta, Tsuyoshi</creator><creator>Eguchi, Chisa</creator><creator>Kojima, Sanae</creator><creator>Minami, Takako</creator><creator>Sato, Daisuke</creator><creator>Eguchi, Masamichi</creator><creator>Okano, Shinji</creator><creator>Ikeda, Satoshi</creator><creator>Ueda, Mitsuharu</creator><creator>Maemura, Koji</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4945-675X</orcidid><orcidid>https://orcid.org/0000-0002-0452-4384</orcidid><orcidid>https://orcid.org/0000-0001-8163-8038</orcidid></search><sort><creationdate>20240430</creationdate><title>Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis</title><author>Nishizawa, Rosy Haruna ; Kawano, Hiroaki ; Yoshimuta, Tsuyoshi ; Eguchi, Chisa ; Kojima, Sanae ; Minami, Takako ; Sato, Daisuke ; Eguchi, Masamichi ; Okano, Shinji ; Ikeda, Satoshi ; Ueda, Mitsuharu ; Maemura, Koji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-85b15bf9854abc9fd4d28979dbeac5ae10c29f08808298c3e1d0247745d464113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amyloid Neuropathies, Familial - complications</topic><topic>Amyloid Neuropathies, Familial - diagnostic imaging</topic><topic>Amyloid Neuropathies, Familial - drug therapy</topic><topic>Atrial Fibrillation - diagnostic imaging</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Benzoxazoles - therapeutic use</topic><topic>Cardiomyopathies - diagnostic imaging</topic><topic>Cardiomyopathies - drug therapy</topic><topic>Cohort Studies</topic><topic>Echocardiography</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Treatment Outcome</topic><topic>Ventricular Dysfunction, Left - diagnostic imaging</topic><topic>Ventricular Dysfunction, Left - drug therapy</topic><topic>Ventricular Dysfunction, Left - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nishizawa, Rosy Haruna</creatorcontrib><creatorcontrib>Kawano, Hiroaki</creatorcontrib><creatorcontrib>Yoshimuta, Tsuyoshi</creatorcontrib><creatorcontrib>Eguchi, Chisa</creatorcontrib><creatorcontrib>Kojima, Sanae</creatorcontrib><creatorcontrib>Minami, Takako</creatorcontrib><creatorcontrib>Sato, Daisuke</creatorcontrib><creatorcontrib>Eguchi, Masamichi</creatorcontrib><creatorcontrib>Okano, Shinji</creatorcontrib><creatorcontrib>Ikeda, Satoshi</creatorcontrib><creatorcontrib>Ueda, Mitsuharu</creatorcontrib><creatorcontrib>Maemura, Koji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal cardiovascular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishizawa, Rosy Haruna</au><au>Kawano, Hiroaki</au><au>Yoshimuta, Tsuyoshi</au><au>Eguchi, Chisa</au><au>Kojima, Sanae</au><au>Minami, Takako</au><au>Sato, Daisuke</au><au>Eguchi, Masamichi</au><au>Okano, Shinji</au><au>Ikeda, Satoshi</au><au>Ueda, Mitsuharu</au><au>Maemura, Koji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis</atitle><jtitle>European heart journal cardiovascular imaging</jtitle><addtitle>Eur Heart J Cardiovasc Imaging</addtitle><date>2024-04-30</date><risdate>2024</risdate><volume>25</volume><issue>5</issue><spage>678</spage><epage>686</epage><pages>678-686</pages><issn>2047-2404</issn><eissn>2047-2412</eissn><abstract>Abstract
Aims
Although tafamidis is used in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), its specific effect on cardiac function is unclear. Thus, this study aimed to investigate the effect of tafamidis on left atrial (LA) and left ventricular function using speckle-tracking echocardiography for 1 year of treatment in patients with ATTRwt-CA.
Methods and results
We included 23 patients (mean age, 76 years) with ATTRwt-CA confirmed via biopsy. We analysed the left ventricular and LA strain using 2D speckle-tracking echocardiography and compared these parameters before and 1 year after starting treatment with tafamidis between 16 patients with sinus rhythm (SR) and 7 patients with atrial fibrillation (AF). In ATTRwt-CA patients with SR, LA reservoir strain significantly improved by 1-year tafamidis treatment (10.5 ± 5.0% to 11.9 ± 5.3%, P = 0.0307) although global longitudinal strain (GLS) did not (−10.6 ± 3.1% to −11.3 ± 3.0%, P = 0.0608). In contrast, LA reservoir strain was not significantly changed (5.4 ± 2.9% to 4.9 ± 1.7%, P = 0.4571), and GLS deteriorated (−8.4 ± 2.3% to −6.8 ± 1.4%, P = 0.0267) in ATTRwt-CA patients with AF.
Conclusion
LA function improved with tafamidis treatment in ATTRwt-CA patients with SR but not left ventricular function. However, these cardiac functions did not improve with tafamidis treatment in ATTRwt-CA patients with AF.
Graphical Abstract
Graphical Abstract</abstract><cop>UK</cop><pub>Oxford University Press</pub><pmid>38109497</pmid><doi>10.1093/ehjci/jead344</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4945-675X</orcidid><orcidid>https://orcid.org/0000-0002-0452-4384</orcidid><orcidid>https://orcid.org/0000-0001-8163-8038</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-2404 |
| ispartof | European heart journal cardiovascular imaging, 2024-04, Vol.25 (5), p.678-686 |
| issn | 2047-2404 2047-2412 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2903859413 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Aged Aged, 80 and over Amyloid Neuropathies, Familial - complications Amyloid Neuropathies, Familial - diagnostic imaging Amyloid Neuropathies, Familial - drug therapy Atrial Fibrillation - diagnostic imaging Atrial Fibrillation - drug therapy Benzoxazoles - therapeutic use Cardiomyopathies - diagnostic imaging Cardiomyopathies - drug therapy Cohort Studies Echocardiography Female Humans Male Treatment Outcome Ventricular Dysfunction, Left - diagnostic imaging Ventricular Dysfunction, Left - drug therapy Ventricular Dysfunction, Left - physiopathology |
| title | Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A33%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20tafamidis%20on%20the%20left%20ventricular%20and%20left%20atrial%20strain%20in%20patients%20with%20wild-type%20transthyretin%20cardiac%20amyloidosis&rft.jtitle=European%20heart%20journal%20cardiovascular%20imaging&rft.au=Nishizawa,%20Rosy%20Haruna&rft.date=2024-04-30&rft.volume=25&rft.issue=5&rft.spage=678&rft.epage=686&rft.pages=678-686&rft.issn=2047-2404&rft.eissn=2047-2412&rft_id=info:doi/10.1093/ehjci/jead344&rft_dat=%3Cproquest_cross%3E2903859413%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2903859413&rft_id=info:pmid/38109497&rft_oup_id=10.1093/ehjci/jead344&rfr_iscdi=true |